||1R50CA252125-01 Interpret this number
||Baylor College Of Medicine
||Functional Genomics of High Grade Glioma
Glioma is the most common and deadly disease affecting the CNS. Current projections suggest 22,000 new
cases annually, of which 13,000 will be Glioblastoma Multiforme, which is universally fatal. Despite over 60
years of research, there have been no significant improvements to patient outcome. More recently, high
throughput molecular sequencing technology has open the field of genomics and big data, in the hopes of
providing novel insight to the disease and potential therapeutic inroads. However, these efforts have largely
served to refine diagnosis rather than improve patient prognosis. In an effort to translate the wealth of patient
genomics information beyond identifying novel informatics trends, our program seeks to biologically
functionalize genomics information. More specifically, we have developed tools and approaches that overcome
the pragmatic hurdles of traditional methods. We have taken our previously developed in utero electroporation-
glioma model and added barcode targeting next generation sequencing, resulting in a fully in vivo, non-viral
screening system to test at least 50 different genetic factors. In advancing forward, we seek to: 1) further
pursue our previous findings to understand the molecular mechanisms driving the phenomenon we’ve
observed, 2) advance and upgrade our methods to meet the needs of other systems, and 3) apply our
approach to investigate glioma-associated epilepsy, an associated co-morbidity. Our larger initiative in
functional genomics will: 1) provide new tools and methods for screening and testing genetic anomalies found
in glioma, 2) provide molecular insight into the mechanism that differentially promote variant specific
gliomagenesis within an allelic series, 3) begin to demonstrate the unique biology of familial glioma, and 4)
further investigate the mechanisms underlying glioma driven hyperexcitably thereby addressing a much under
investigated quality of life concern. Ultimately, our programs exists to gain greater insight into the molecular
mechanisms that drive gliomagenesis and associated co-morbidities. This will provide understanding towards
novel therapeutic vulnerabilities.
POT1 Regulates Proliferation and Confers Sexual Dimorphism in Glioma.
, Yu K.
, Beechar V.
, Bosquez Huerta N.A.
, Grichuk A.
, Mehra D.
, Lozzi B.
, Kong K.
, Scott K.L.
, Rao G.
, et al.
Cancer research, 2021-05-15; 81(10), p. 2703-2713.